# Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer

Source: https://onco.cc/trials/nct04114825/  
OnCo record `nct04114825` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of RV001V in prostate cancer, run by RhoVac APS, active and no longer recruiting.

## Summary

Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer is a phase 2 interventional study registered as NCT04114825 by RhoVac APS, with 180 participants enrolled, started 2019-11-19 and due to reach its primary completion in 2022-04. Interventions recorded: RV001V.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04114825
- Phase: 2
- Setting: A Phase 2, Double-Blind, Placebo Controlled Study of RV001V in Men With Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer (BRaVac)
- Sponsor: RhoVac APS
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT04114825: https://clinicaltrials.gov/study/NCT04114825

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [RV001V](https://onco.cc/drugs/rv001v/)

---
JSON: https://onco.cc/api/v1/entities/nct04114825.json